Phathom Pharmaceuticals (PHAT) Price & Analysis

Compare

523 Followers

PHAT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.21 - $19.71

Previous CloseN/A

Volume285.74K

Average Volume (3M)1.11M

Market Cap

$892.47M

Enterprise Value$1.12B

Total Cash (Recent Filing)$212.31M

Total Debt (Recent Filing)$203.56M

Price to Earnings (P/E)―

Beta2.08

Next Earnings

Nov 06, 2025

EPS Estimate

-0.47

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.05

Shares Outstanding70,943,710

10 Day Avg. Volume1,108,600

30 Day Avg. Volume1,108,407

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.25

Enterprise Value/Revenue13.68

Enterprise Value/Gross Profit15.86

Enterprise Value/Ebitda-4.07

Forecast

1Y Price Target

$21.57

Price Target Upside73.39% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

FDA ApprovalFDA's decision to approve the company's Citizen's Petition and recognize Voquezna's full 10-year exclusivity removes a big overhang on the stock.

Investor SentimentInvestor sentiment following the NCE announcement demonstrated a vote of confidence, with PHAT shares closing up approximately 90%.

Revenue GrowthThe company has demonstrated sequential revenue growth while utilizing strategic cost reductions.

Bears Say

Market ChallengesThe BlinkRx option gives prescribers and new patients a means to access VOQUEZNA therapy despite prospective coverage pushback.

Stock VolatilityShares were severely punished—beyond what was the underlying value with only two years of exclusivity lost.

Phathom Pharmaceuticals News

Phathom clarifies no reduction in lead shareholder’s ownership amid 13D filing

Phathom Pharmaceuticals (PHAT) clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be...

9d ago

PHAT

Phathom Pharmaceuticals reports Q2 EPS (79c), consensus (89c)

Reports Q2 revenue $39.5M, consensus $35.58M. “The second quarter marked a significant step forward in Phathom’s journey toward...

22d ago

PHAT

Phathom Pharmaceuticals sees 2025 revenue $165M-$175M, consensus $159.4M

07:27 EDT Phathom Pharmaceuticals (PHAT) sees 2025 revenue $165M-$175M, consensus $159.4M Published first on TheFly – the ultimate...

22d ago

PHAT

Phathom Pharmaceuticals’ Earnings Call Highlights Growth and Challenges

Phathom Pharmaceuticals, Inc. (($PHAT)) has held its Q2 earnings call. Read on for the main highlights of the...

16d ago

PHAT

Phathom Pharmaceuticals Reports Strong Q2 Growth

Phathom Pharmaceuticals, Inc. ( ($PHAT) ) has released its Q2 earnings. Here is a breakdown of the information...

21d ago

PHAT

Phathom Pharmaceuticals: Strong Buy Rating Driven by Robust Revenue Performance and Growth Potential

In a report released today, Joseph Stringer from Needham maintained a Buy rating on Phathom Pharmaceuticals, with a...

21d ago

PHAT

Avidity, Phathom mentioned as potential takeout targets at Needham

Needham, in a research note to investors on the biotech industry, mentioned Avidity (RNA) and Phathom Pharmaceuticals (PHAT)...

1M ago

BMY

NVO

Phathom Pharmaceuticals appoints Anne Marie Cook as CLO, corporate secretary

Phathom Pharmaceuticals (PHAT) announced the appointment of Anne Marie Cook, J.D., as Chief Legal Officer and Corporate Secretary....

2M ago

PHAT

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Chime Financial, Inc. (CHYM)...

2M ago

RKT

BLNK

Phathom Pharmaceuticals Gains FDA Exclusivity for VOQUEZNA

Phathom Pharmaceuticals ( ($PHAT) ) has provided an update. On June 16, 2025, Phathom Pharmaceuticals announced that the...

2M ago

PHAT

Phathom Pharmaceuticals announces FDA correction to Orange Book Listing

Phathom Pharmaceuticals (PHAT) announced that the U.S. Food and Drug Administration, FDA, has updated the Approved Drug Products...

2M ago

PHAT

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Beyond Meat (BYND) 86.64%...

3M ago

RDW

ALMS

Phathom Pharmaceuticals Holds Annual Stockholders Meeting

Phathom Pharmaceuticals ( ($PHAT) ) just unveiled an announcement. On June 3, 2025, Phathom Pharmaceuticals held its Annual...

3M ago

PHAT

Phathom Pharmaceuticals price target raised to $17 from $12 at Craig-Hallum

Craig-Hallum raised the firm’s price target on Phathom Pharmaceuticals (PHAT) to $17 from $12 and keeps a Buy...

3M ago

PHAT

PHAT FAQ

What was Phathom Pharmaceuticals’s price range in the past 12 months?

Phathom Pharmaceuticals lowest stock price was $2.21 and its highest was $19.71 in the past 12 months.

What is Phathom Pharmaceuticals’s market cap?

Phathom Pharmaceuticals’s market cap is $892.47M.

When is Phathom Pharmaceuticals’s upcoming earnings report date?

Phathom Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.

How were Phathom Pharmaceuticals’s earnings last quarter?

Phathom Pharmaceuticals released its earnings results on Aug 07, 2025. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.95 by -$0.1.

Is Phathom Pharmaceuticals overvalued?

According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Phathom Pharmaceuticals pay dividends?

Phathom Pharmaceuticals does not currently pay dividends.

What is Phathom Pharmaceuticals’s EPS estimate?

Phathom Pharmaceuticals’s EPS estimate is -0.47.

How many shares outstanding does Phathom Pharmaceuticals have?

Phathom Pharmaceuticals has 70,943,710 shares outstanding.

What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?

Phathom Pharmaceuticals reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.95. Following the earnings report the stock price went up 8.295%.

Which hedge fund is a major shareholder of Phathom Pharmaceuticals?

Currently, no hedge funds are holding shares in PHAT

Phathom Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

181.41%

Trailing 12-Months

Asset Growth

-21.65%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Phathom Pharmaceuticals

Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Phathom Pharmaceuticals (PHAT) Earnings & Revenues

Historic Earnings Reports

PHAT Company Deck

PHAT Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects strong growth in prescription numbers and revenue, successful cost management, and a positive resolution regarding product exclusivity. However, there are potential challenges with supply disruptions and Medicare coverage. The strategic focus on gastroenterologists is expected to drive further growth.View all PHAT earnings summaries

PHAT Stock 12 Month Forecast

Average Price Target

$21.57

▲(73.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","9":"$9","16":"$16","23":"$23","30":"$30"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$29.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":21.57,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$21.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9,16,23,30],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.35,9.938461538461539,11.526923076923076,13.115384615384615,14.703846153846154,16.29230769230769,17.880769230769232,19.46923076923077,21.057692307692307,22.646153846153844,24.23461538461538,25.82307692307692,27.411538461538463,{"y":29,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.35,9.366923076923076,10.383846153846154,11.400769230769232,12.417692307692308,13.434615384615384,14.451538461538462,15.46846153846154,16.485384615384618,17.502307692307696,18.51923076923077,19.536153846153844,20.553076923076922,{"y":21.57,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.35,8.63076923076923,8.911538461538461,9.192307692307692,9.473076923076922,9.753846153846153,10.034615384615384,10.315384615384616,10.596153846153847,10.876923076923077,11.157692307692308,11.438461538461539,11.71923076923077,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.81,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.43,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.52,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.27,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.71,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.99,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.12,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.36,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.64,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.85,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.35,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >